Egalet Corp. is going to have to wait a small longer to find out if the Food and Drug Administration is going to approve the company's tamper-resistant pain medicine Arymo ER.
The FDA has informed the specialty pharmaceutical company that the federal agency will not meet the previously announced Oct.14 prescription drug user fee act (PDUFA) date for making a decision on the company's application.
"We were informed that the FDA has identified no specific issue with our application for Arymo ER,…
Source: bizjournals.com